Investors should monitor upcoming BLA submission in Q3 2026 and Phase 3 topline data in Q1 2027 as key catalysts. The gene-agnostic mechanism could position OCU400 as a first-in-class therapy with broad market potential.
OCGN drugs
OCGN drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $1.94entry
- T+1 · 9mo ago −4.12%α −3.21% · $1.86
- T+5 · 8mo ago −14.43%α −13.23% · $1.66
- T+20 · 8mo ago −9.79%α −1.86% · $1.75
- T+60 · 6mo ago −30.93%α −40.25% · $1.34
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ocugen announced completion of patient enrollment in the Phase 3 liMeliGhT trial for its gene therapy OCU400 in retinitis pigmentosa (RP), with topline data expected in Q1 2027. The company also reported positive 3-year Phase 1/2 data showing durable vision improvement and a favorable safety profile, reinforcing the potential for a gene-agnostic treatment. BLA filing is on track for Q3 2026.
Key Facts
- Enrollment completed in OCU400 Phase 3 liMeliGhT trial with 140 patients randomized 2:1 across RHO and gene-agnostic RP mutations.
- Topline Phase 3 data expected in Q1 2027, supporting potential approval in 2027.
- Positive 3-year Phase 1/2 data show 88% of treated eyes maintained or improved vision, with ~2-line LLVA gain sustained across mutations.
- No new treatment-related serious adverse events reported; safety profile remains favorable.
- Rolling BLA submission planned for Q3 2026; EMA accepts U.S. trial data for future MAA submission.
Financial Impact
Potential blockbuster revenue if approved, given no current gene-agnostic therapy for RP and ~98% of RP patients lack treatment options.
Risk Factors
- Phase 3 results may not replicate Phase 1/2 durability or efficacy.
- Regulatory delays or rejection despite EMA acceptability opinion.
- High development risk typical of gene therapies in late-stage trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247241 |
Track record
23 reports on OCGN
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
- Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
- Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
- Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
- Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
- Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers